Intrinsic value of MiMedx Group - MDXG

Previous Close

$13.80

  Intrinsic Value

premium content

  Rating & Target

premium content

  Value-price divergence*

premium content

Previous close

$13.80

 
Intrinsic value

$9.37

 
Up/down potential

-32%

 
Rating

sell

 
Value-price divergence* premium content

Premium access subscription - $499/yr

please register and log in before paying

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of MDXG stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.6

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  31.02
  37.70
  34.43
  31.49
  28.84
  26.45
  24.31
  22.38
  20.64
  19.08
  17.67
  16.40
  15.26
  14.24
  13.31
  12.48
  11.73
  11.06
  10.45
  9.91
  9.42
  8.98
  8.58
  8.22
  7.90
  7.61
  7.35
  7.11
  6.90
  6.71
  6.54
Revenue, $m
  245
  337
  454
  596
  768
  972
  1,208
  1,478
  1,783
  2,123
  2,498
  2,908
  3,352
  3,829
  4,339
  4,880
  5,453
  6,056
  6,689
  7,352
  8,044
  8,766
  9,518
  10,300
  11,114
  11,959
  12,838
  13,751
  14,700
  15,687
  16,713
Variable operating expenses, $m
 
  294
  394
  518
  666
  842
  1,046
  1,280
  1,544
  1,838
  2,163
  2,515
  2,899
  3,311
  3,752
  4,221
  4,716
  5,237
  5,785
  6,358
  6,957
  7,581
  8,231
  8,908
  9,612
  10,343
  11,103
  11,893
  12,713
  13,567
  14,454
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  227
  294
  394
  518
  666
  842
  1,046
  1,280
  1,544
  1,838
  2,163
  2,515
  2,899
  3,311
  3,752
  4,221
  4,716
  5,237
  5,785
  6,358
  6,957
  7,581
  8,231
  8,908
  9,612
  10,343
  11,103
  11,893
  12,713
  13,567
  14,454
Operating income, $m
  18
  44
  59
  79
  102
  129
  161
  198
  239
  285
  336
  393
  453
  518
  586
  660
  737
  819
  904
  994
  1,087
  1,185
  1,286
  1,392
  1,502
  1,616
  1,735
  1,859
  1,987
  2,120
  2,259
EBITDA, $m
  23
  50
  68
  89
  115
  145
  180
  221
  266
  317
  373
  435
  501
  572
  648
  729
  815
  905
  999
  1,098
  1,202
  1,310
  1,422
  1,539
  1,661
  1,787
  1,918
  2,055
  2,196
  2,344
  2,497
Interest expense (income), $m
  0
  0
  1
  2
  3
  4
  6
  8
  11
  13
  16
  19
  23
  27
  31
  35
  40
  45
  50
  55
  61
  67
  73
  79
  86
  93
  100
  108
  116
  124
  132
Earnings before tax, $m
  18
  44
  59
  77
  99
  125
  155
  190
  228
  272
  320
  374
  430
  491
  556
  625
  697
  774
  854
  939
  1,026
  1,118
  1,214
  1,313
  1,416
  1,523
  1,635
  1,751
  1,871
  1,997
  2,127
Tax expense, $m
  6
  12
  16
  21
  27
  34
  42
  51
  62
  73
  86
  101
  116
  133
  150
  169
  188
  209
  231
  253
  277
  302
  328
  354
  382
  411
  441
  473
  505
  539
  574
Net income, $m
  12
  32
  43
  56
  72
  91
  113
  138
  167
  198
  233
  273
  314
  358
  406
  456
  509
  565
  624
  685
  749
  816
  886
  958
  1,034
  1,112
  1,194
  1,278
  1,366
  1,457
  1,553

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  34
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  193
  219
  294
  387
  499
  630
  784
  959
  1,157
  1,378
  1,621
  1,887
  2,175
  2,485
  2,816
  3,167
  3,539
  3,930
  4,341
  4,771
  5,220
  5,689
  6,176
  6,684
  7,212
  7,761
  8,331
  8,924
  9,540
  10,180
  10,846
Adjusted assets (=assets-cash), $m
  159
  219
  294
  387
  499
  630
  784
  959
  1,157
  1,378
  1,621
  1,887
  2,175
  2,485
  2,816
  3,167
  3,539
  3,930
  4,341
  4,771
  5,220
  5,689
  6,176
  6,684
  7,212
  7,761
  8,331
  8,924
  9,540
  10,180
  10,846
Revenue / Adjusted assets
  1.541
  1.539
  1.544
  1.540
  1.539
  1.543
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
Average production assets, $m
  28
  38
  52
  68
  88
  111
  138
  168
  203
  242
  285
  332
  382
  437
  495
  556
  622
  690
  763
  838
  917
  999
  1,085
  1,174
  1,267
  1,363
  1,464
  1,568
  1,676
  1,788
  1,905
Working capital, $m
  76
  58
  78
  102
  131
  166
  207
  253
  305
  363
  427
  497
  573
  655
  742
  835
  932
  1,036
  1,144
  1,257
  1,376
  1,499
  1,628
  1,761
  1,900
  2,045
  2,195
  2,351
  2,514
  2,682
  2,858
Total debt, $m
  0
  23
  51
  86
  128
  178
  235
  302
  376
  459
  551
  651
  760
  877
  1,001
  1,134
  1,274
  1,422
  1,576
  1,739
  1,908
  2,085
  2,269
  2,460
  2,659
  2,866
  3,081
  3,304
  3,536
  3,778
  4,029
Total liabilities, $m
  60
  83
  111
  146
  188
  238
  295
  362
  436
  519
  611
  711
  820
  937
  1,061
  1,194
  1,334
  1,482
  1,636
  1,799
  1,968
  2,145
  2,329
  2,520
  2,719
  2,926
  3,141
  3,364
  3,596
  3,838
  4,089
Total equity, $m
  133
  136
  183
  241
  311
  393
  488
  598
  721
  858
  1,010
  1,176
  1,355
  1,548
  1,754
  1,973
  2,204
  2,448
  2,704
  2,972
  3,252
  3,544
  3,848
  4,164
  4,493
  4,835
  5,190
  5,559
  5,943
  6,342
  6,757
Total liabilities and equity, $m
  193
  219
  294
  387
  499
  631
  783
  960
  1,157
  1,377
  1,621
  1,887
  2,175
  2,485
  2,815
  3,167
  3,538
  3,930
  4,340
  4,771
  5,220
  5,689
  6,177
  6,684
  7,212
  7,761
  8,331
  8,923
  9,539
  10,180
  10,846
Debt-to-equity ratio
  0.000
  0.170
  0.280
  0.360
  0.410
  0.450
  0.480
  0.500
  0.520
  0.540
  0.550
  0.550
  0.560
  0.570
  0.570
  0.570
  0.580
  0.580
  0.580
  0.580
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.600
  0.600
  0.600
Adjusted equity ratio
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  12
  32
  43
  56
  72
  91
  113
  138
  167
  198
  233
  273
  314
  358
  406
  456
  509
  565
  624
  685
  749
  816
  886
  958
  1,034
  1,112
  1,194
  1,278
  1,366
  1,457
  1,553
Depreciation, amort., depletion, $m
  5
  7
  8
  10
  13
  16
  19
  23
  27
  32
  38
  41
  48
  55
  62
  70
  78
  86
  95
  105
  115
  125
  136
  147
  158
  170
  183
  196
  209
  224
  238
Funds from operations, $m
  15
  39
  51
  67
  85
  107
  132
  161
  194
  231
  271
  314
  362
  413
  468
  525
  587
  651
  719
  790
  864
  941
  1,021
  1,105
  1,192
  1,283
  1,376
  1,474
  1,576
  1,681
  1,791
Change in working capital, $m
  -11
  16
  20
  24
  29
  35
  40
  46
  52
  58
  64
  70
  76
  82
  87
  93
  98
  103
  108
  113
  118
  123
  129
  134
  139
  145
  150
  156
  162
  169
  175
Cash from operations, $m
  26
  31
  31
  42
  56
  72
  92
  115
  142
  173
  207
  244
  286
  331
  380
  433
  489
  548
  611
  677
  746
  818
  893
  971
  1,053
  1,138
  1,226
  1,318
  1,413
  1,512
  1,615
Maintenance CAPEX, $m
  0
  -4
  -5
  -6
  -8
  -11
  -14
  -17
  -21
  -25
  -30
  -36
  -41
  -48
  -55
  -62
  -70
  -78
  -86
  -95
  -105
  -115
  -125
  -136
  -147
  -158
  -170
  -183
  -196
  -209
  -224
New CAPEX, $m
  -6
  -10
  -13
  -16
  -20
  -23
  -27
  -31
  -35
  -39
  -43
  -47
  -51
  -54
  -58
  -62
  -65
  -69
  -72
  -76
  -79
  -82
  -86
  -89
  -93
  -96
  -100
  -104
  -108
  -112
  -117
Cash from investing activities, $m
  -12
  -14
  -18
  -22
  -28
  -34
  -41
  -48
  -56
  -64
  -73
  -83
  -92
  -102
  -113
  -124
  -135
  -147
  -158
  -171
  -184
  -197
  -211
  -225
  -240
  -254
  -270
  -287
  -304
  -321
  -341
Free cash flow, $m
  14
  17
  13
  19
  28
  38
  51
  67
  86
  108
  134
  162
  194
  229
  268
  309
  354
  402
  452
  506
  562
  621
  682
  747
  813
  883
  956
  1,031
  1,109
  1,190
  1,275
Issuance/(repayment) of debt, $m
  0
  23
  28
  35
  42
  50
  58
  66
  75
  83
  92
  100
  109
  117
  125
  132
  140
  148
  155
  162
  169
  177
  184
  191
  199
  207
  215
  223
  232
  241
  251
Issuance/(repurchase) of shares, $m
  -8
  0
  5
  3
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -8
  23
  33
  38
  42
  50
  58
  66
  75
  83
  92
  100
  109
  117
  125
  132
  140
  148
  155
  162
  169
  177
  184
  191
  199
  207
  215
  223
  232
  241
  251
Total cash flow (excl. dividends), $m
  6
  39
  42
  54
  70
  88
  109
  133
  161
  192
  226
  262
  302
  346
  392
  442
  494
  549
  607
  668
  731
  797
  866
  938
  1,013
  1,090
  1,171
  1,254
  1,341
  1,432
  1,526
Retained Cash Flow (-), $m
  -25
  -37
  -47
  -58
  -70
  -82
  -95
  -109
  -123
  -138
  -152
  -166
  -179
  -193
  -206
  -219
  -231
  -244
  -256
  -268
  -280
  -292
  -304
  -316
  -329
  -342
  -355
  -369
  -384
  -399
  -415
Prev. year cash balance distribution, $m
 
  34
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  36
  0
  0
  0
  6
  14
  24
  37
  54
  74
  96
  123
  153
  186
  223
  263
  305
  351
  400
  451
  505
  562
  622
  684
  748
  815
  885
  958
  1,033
  1,111
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  35
  0
  0
  0
  4
  10
  16
  23
  31
  39
  46
  53
  58
  63
  65
  67
  66
  65
  62
  57
  52
  47
  41
  35
  29
  24
  19
  15
  11
  8
Current shareholders' claim on cash, %
  100
  100.0
  99.6
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4
  99.4

MiMedx Group, Inc. develops, processes, and markets patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues, and human skin and bone. Its biomaterial product families include dHACM family with AmnioFix and EpiFix brands; Amniotic Fluid family with OrthoFlo brand; Umbilical family with EpiCord and AmnioCord brands; Placental Collagen family with CollaFix brands; Bone family with Physio brand; and Skin family with AlloBurn brand. The company’s AmnioFix, EpiFix, and EpiBurn are tissue technologies processed from human amniotic membrane; OrthoFlo is an amniotic fluid derived allograft; EpiCord and AmnioCord are derived from the umbilical cord; Physio is a unique bone grafting material comprised of 100% bone tissue with no added carrier; and AlloBurn is a skin product derived from human skin designed for the treatment of burns. It also focuses on commercializing CollaFix, a collagen fiber technology developed with its patented cross-linking polymers to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues in order to augment their repair. The company processes the human amniotic membrane utilizing its proprietary PURION process to produce a safe and effective implant. MiMedx supplies amniotic tissue for application in the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors. Its proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. The company sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. The company is headquartered in Marietta, Georgia.

FINANCIAL RATIOS  of  MiMedx Group (MDXG)

Valuation Ratios
P/E Ratio 126.3
Price to Sales 6.2
Price to Book 11.4
Price to Tangible Book
Price to Cash Flow 58.3
Price to Free Cash Flow 75.8
Growth Rates
Sales Growth Rate 31%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate 24.6%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 7.3%
Ret/ On Assets - 3 Yr. Avg. 12.4%
Return On Total Capital 10%
Ret/ On T. Cap. - 3 Yr. Avg. 15.6%
Return On Equity 10%
Return On Equity - 3 Yr. Avg. 15.6%
Asset Turnover 1.5
Profitability Ratios
Gross Margin 86.9%
Gross Margin - 3 Yr. Avg. 88.7%
EBITDA Margin 9.4%
EBITDA Margin - 3 Yr. Avg. 10.5%
Operating Margin 7.3%
Oper. Margin - 3 Yr. Avg. 8.7%
Pre-Tax Margin 7.3%
Pre-Tax Margin - 3 Yr. Avg. 8.7%
Net Profit Margin 4.9%
Net Profit Margin - 3 Yr. Avg. 8.5%
Effective Tax Rate 33.3%
Eff/ Tax Rate - 3 Yr. Avg. 8.9%
Payout Ratio 0%

MDXG stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MDXG stock intrinsic value calculation we used $245 million for the last fiscal year's total revenue generated by MiMedx Group. The default revenue input number comes from 2016 income statement of MiMedx Group. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our MDXG stock valuation model: a) initial revenue growth rate of 37.7% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for MDXG is calculated based on our internal credit rating of MiMedx Group, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of MiMedx Group.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MDXG stock the variable cost ratio is equal to 87.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for MDXG stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for MiMedx Group.

Corporate tax rate of 27% is the nominal tax rate for MiMedx Group. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MDXG stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MDXG are equal to 11.4%.

Life of production assets of 8 years is the average useful life of capital assets used in MiMedx Group operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MDXG is equal to 17.1%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $133 million for MiMedx Group - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 112.319 million for MiMedx Group is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of MiMedx Group at the current share price and the inputted number of shares is $1.6 billion.


Premium access subscription - $499/yr

please register and log in before paying

COMPANY NEWS

▶ Can This 2015 Medical IPO Inject New Life Into Its Stock?   [May-24-17 12:03PM  Investor's Business Daily]
▶ MiMedx EpiFix® Receives Coverage From Kaiser Permanente   [May-04-17 08:30AM  PR Newswire]
▶ Merger Buzz Drives Akorn to Top of Health Chart in April   [Apr-30-17 04:20PM  TheStreet.com]
▶ MiMedx beats 1Q profit forecasts   [07:28AM  Associated Press]
▶ 4 Stocks With Strong Technical Momentum   [Apr-21-17 08:40AM  Benzinga]
▶ ETFs with exposure to MiMedx Group, Inc. : April 17, 2017   [Apr-17-17 12:58PM  Capital Cube]
▶ ETFs with exposure to MiMedx Group, Inc. : April 5, 2017   [Apr-05-17 05:05PM  Capital Cube]
▶ MiMedx Announces 2016 Record Results   [07:30AM  PR Newswire]
▶ MiMedx Announces Release Date for 2016 Full Year Results   [Feb-16-17 05:04PM  PR Newswire]
▶ MiMedx EpiFix Receives Coverage From Aetna   [Dec-27-16 04:02PM  PR Newswire]
▶ MiMedx Comments on Meritless Lawsuit   [Dec-15-16 04:01PM  PR Newswire]
▶ Is MiMedx Group Inc (MDXG) A Good Stock To Buy?   [Dec-14-16 06:00PM  at Insider Monkey]
▶ MiMedx Is Grand Sponsor Of Desert Foot 2016   [Oct-18-16 10:03AM  PR Newswire]
▶ MiMedx Reaffirms Q3 and Full Year 2016 Guidance   [Sep-06-16 08:30AM  PR Newswire]
▶ MiMedx Announces Nationwide Launch of AmnioFill   [Sep-01-16 04:13PM  PR Newswire]
▶ MiMedx Provides Update On Key Clinical Trials   [Aug-30-16 06:10PM  PR Newswire]
Stock chart of MDXG Financial statements of MDXG Annual reports of MDXG
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.